The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury
Abstract
Background. Neutralization of central nervous system neurite growth inhibitory factors, for example, Nogo-A, is a promising approach to improving recovery following spinal cord injury (SCI). In animal SCI models, intrathecal delivery of anti-Nogo-A antibodies promoted regenerative neurite growth and functional recovery. Objective. This first-in-man study assessed the feasibility, safety, tolerability, pharmacokinetics, and preliminary efficacy of the human anti-Nogo-A antibody ATI355 following intrathecal administration in patients with acute, complete traumatic paraplegia and tetraplegia. Methods. Patients (N = 52) started treatment 4 to 60 days postinjury. Four consecutive dose-escalation cohorts received 5 to 30 mg/2.5 mL/day continuous intrathecal ATI355 infusion over 24 hours to 28 days. Following pharmacokinetic evaluation, 2 further cohorts received a bolus regimen (6 intrathecal injections of 22.5 and 45 mg/3 mL, respectively, over 4 weeks). Results. ATI355 was well tolerated up to 1-year follow-up. All patients experienced ≥1 adverse events (AEs). The 581 reported AEs were mostly mild and to be expected following acute SCI. Fifteen patients reported 16 serious AEs, none related to ATI355; one bacterial meningitis case was considered related to intrathecal administration. ATI355 serum levels showed dose-dependency, and intersubject cerebrospinal fluid levels were highly variable after infusion and bolus injection. In 1 paraplegic patient, motor scores improved by 8 points. In tetraplegic patients, mean total motor scores increased, with 3/19 gaining >10 points, and 1/19 27 points at Week 48. Conversion from complete to incomplete SCI occurred in 7/19 patients with tetraplegia. Conclusions. ATI335 was well tolerated in humans; efficacy trials using intrathecal antibody administration may be considered in acute SCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular disease and spinal cord injury: Results from a national population health survey
Cragg, J. J., Noonan, V. K., Krassioukov, A., & Borisoff, J. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a1aa68 · Cited by 342
Freund, P., Schmidlin, E., Wannier, T., Bloch, J., Mir, A., Schwab, M. E., & Rouiller, E. M. (2006) · Nature Medicine · doi:10.1038/nm1436 · Cited by 335
Self-citation
Cited by
Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets
Ng, S. Y., & Lee, A. Y. W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00528 · Cited by 852
The translational landscape in spinal cord injury: focus on neuroplasticity and regeneration
Hutson, T. H., & Di Giovanni, S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0280-3 · Cited by 302
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.002 · Cited by 95
Metadata
- Authors
- Kucher, K., Johns, D., Maier, D., Abel, R., Badke, A., Baron, H., Thietje, R., Casha, S., Meindl, R., Gomez-Mancilla, B., Pfister, C., Rupp, R., Weidner, N., Mir, A., Schwab, M. E., & Curt, A.
- Venue
- Neurorehabilitation and Neural Repair
- Publisher
- SAGE Publications
- Published
- 2018-06
- Volume
- 32
- Issue
- 6-7
- Pages
- 578-589
- ISSN
- 0888-4390 (ISSN-L)
- 1545-9683
- 1552-6844
- OpenAlex
- W2805352311
- Cited by
- 195
- References
- 2
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury. https://app.cochat.ai/papers/10.1177/1545968318776371
- The paper
- Kucher, K., Johns, D., Maier, D., Abel, R., Badke, A., Baron, H., Thietje, R., Casha, S., Meindl, R., Gomez-Mancilla, B., Pfister, C., Rupp, R., Weidner, N., Mir, A., Schwab, M. E., & Curt, A. (2018). First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury. Neurorehabilitation and Neural Repair. https://doi.org/10.1177/1545968318776371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.